JP2001514167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001514167A5 JP2001514167A5 JP2000507650A JP2000507650A JP2001514167A5 JP 2001514167 A5 JP2001514167 A5 JP 2001514167A5 JP 2000507650 A JP2000507650 A JP 2000507650A JP 2000507650 A JP2000507650 A JP 2000507650A JP 2001514167 A5 JP2001514167 A5 JP 2001514167A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- ocf
- group selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 24
- 229910052801 chlorine Inorganic materials 0.000 description 23
- 229910052736 halogen Inorganic materials 0.000 description 18
- 150000002367 halogens Chemical class 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 229910052794 bromium Inorganic materials 0.000 description 17
- 229910052731 fluorine Inorganic materials 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- -1 2-benzothiazolyl ring Chemical group 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/917,025 | 1997-08-22 | ||
| US08/917,025 US6284923B1 (en) | 1997-08-22 | 1997-08-22 | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| PCT/US1998/016781 WO1999010320A1 (en) | 1997-08-22 | 1998-08-13 | Substituted benzene compounds as antiproliferative and cholesterol lowering agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001514167A JP2001514167A (ja) | 2001-09-11 |
| JP2001514167A5 true JP2001514167A5 (enExample) | 2006-01-05 |
| JP4309041B2 JP4309041B2 (ja) | 2009-08-05 |
Family
ID=25438246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000507650A Expired - Fee Related JP4309041B2 (ja) | 1997-08-22 | 1998-08-13 | 細胞増殖抑制薬およびコレステロール低下剤としての置換ベンゼン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6284923B1 (enExample) |
| EP (1) | EP1005453B1 (enExample) |
| JP (1) | JP4309041B2 (enExample) |
| AT (1) | ATE280756T1 (enExample) |
| AU (1) | AU748826B2 (enExample) |
| CA (1) | CA2301842C (enExample) |
| DE (1) | DE69827267T2 (enExample) |
| ES (1) | ES2245803T3 (enExample) |
| PT (1) | PT1005453E (enExample) |
| WO (1) | WO1999010320A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE249213T1 (de) * | 1996-02-22 | 2003-09-15 | Tularik Inc | Pentafluorobenzensulfonamiden und analoge |
| US6482860B1 (en) * | 1996-07-19 | 2002-11-19 | Tularik Inc. | Pentafluorobenzenesulfonamides and analogs |
| AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| EP1090014B1 (en) * | 1998-06-25 | 2003-09-03 | Tularik Inc. | Arylsulfonanilide phosphates |
| EE200100302A (et) * | 1998-12-02 | 2002-08-15 | Pfizer Products Inc. | Meetodid ja kompositsioonid p53 perekonna valgu konformatsioonilise stabiilsuse taastamiseks |
| WO2001000579A1 (en) * | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US6306615B1 (en) | 1999-08-19 | 2001-10-23 | Tularik Inc. | Detection method for monitoring β tubulin isotype specific modification |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| AU2002234165A1 (en) | 2000-11-03 | 2002-05-27 | Tularik, Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| US20050250854A1 (en) * | 2000-11-03 | 2005-11-10 | Amgen Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| JP4448902B2 (ja) * | 2001-06-08 | 2010-04-14 | 株式会社医薬分子設計研究所 | スルホンアミド誘導体 |
| JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| US7833734B2 (en) * | 2002-11-26 | 2010-11-16 | Institute Of Virology Of The Slovak Academy Of Sciences | CA IX-specific inhibitors |
| JP4713341B2 (ja) * | 2002-11-26 | 2011-06-29 | インスティトゥート オブ ヴァイロロジー | Ｃａ−ｉｘ特異的阻害剤 |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| FI20055498A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
| GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| EP2632920A1 (en) * | 2010-10-27 | 2013-09-04 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of pkm2 |
| EP2925717A4 (en) * | 2012-11-28 | 2016-08-03 | Stichting Dienst Landbouwkundi | BENZOLSULFONAMIDE COMPOUNDS FOR PLANTS WITH SOMATIC EMBRYOGENESIS I |
| DE112014003266T5 (de) * | 2013-08-28 | 2016-03-31 | Borgwarner Inc. | Hochtemperatur-Ventilschaftdichtung |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| AU2018218518B2 (en) | 2017-02-07 | 2022-03-17 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| US11168069B2 (en) | 2017-02-07 | 2021-11-09 | Oblique Therapeutics Ab | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| EP3580215A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| US11555012B2 (en) * | 2018-11-09 | 2023-01-17 | Nimbus Artemis, Inc. | ACLY inhibitors and uses thereof |
| WO2021009568A1 (en) * | 2019-07-17 | 2021-01-21 | 2692372 Ontario, Inc. | Benzenesulfonamide derivatives and uses thereof |
| CA3254120A1 (en) * | 2022-03-21 | 2023-09-28 | Chemocentryx, Inc. | CXCR6 SULFONAMIDE COMPOUNDS |
| WO2024175999A2 (en) * | 2023-02-23 | 2024-08-29 | Dunad Therapeutics Ltd. | Benzenesulfonamide derivatives and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1955207A (en) | 1931-09-16 | 1934-04-17 | Ig Farbenindustrie Ag | Mothproofing agent |
| DE622494C (de) | 1932-01-03 | 1935-11-29 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten |
| US2358365A (en) | 1940-08-03 | 1944-09-19 | Parke Davis & Co | Sulphonamide derivatives and process for obtaining the same |
| US2450863A (en) | 1946-03-07 | 1948-10-05 | Socony Vacuum Oil Co Inc | Amides from sulfonyl fluorides |
| CH362688A (de) | 1957-09-10 | 1962-06-30 | Geigy Ag J R | Verfahren zur Herstellung von neuen Arylsulfonarylamiden |
| US2937202A (en) | 1958-05-19 | 1960-05-17 | Dow Chemical Co | Substituted benzenesulfonanilides |
| GB938890A (en) | 1961-02-03 | 1963-10-09 | Boots Pure Drug Co Ltd | New fungicidal compositions and compounds |
| NL301745A (enExample) | 1962-12-17 | |||
| CH504416A (de) * | 1966-12-05 | 1971-03-15 | Ciba Geigy Ag | Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen |
| US3505455A (en) | 1966-12-15 | 1970-04-07 | Ansul Co | Nematocidal method |
| NL174644C (nl) | 1970-04-13 | 1984-07-16 | Minnesota Mining & Mfg | Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking. |
| US3951910A (en) * | 1973-12-28 | 1976-04-20 | General Electric Company | Flame retardant polycarbonate composition |
| US4013621A (en) | 1975-04-29 | 1977-03-22 | Ciba-Geigy Corporation | Substituted sulfonamide derivatives of hindered phenols and stabilized compositions |
| DE2528697C2 (de) | 1975-06-27 | 1986-02-20 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Salicylaldehyden |
| US4034110A (en) | 1976-09-20 | 1977-07-05 | Hoffmann-La Roche Inc. | Anthelmintics effective against liver flukes |
| US4239699A (en) | 1978-05-24 | 1980-12-16 | Henkel Corporation | Sulfonamidophenols, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values |
| US4373017A (en) | 1980-03-05 | 1983-02-08 | Konishiroku Photo Industry Co., Ltd. | Photosensitive compound and photosensitive material containing it |
| US4483986A (en) | 1982-05-03 | 1984-11-20 | Eli Lilly And Company | 4-Nitrobenzophenone compounds |
| NZ215272A (en) | 1985-02-27 | 1989-08-29 | Mitsui Toatsu Chemicals | Fungicidal n-(2-chloro-4-nitrophenyl)-benzenesulphonamide derivatives and compositions thereof |
| US4692466A (en) | 1985-02-28 | 1987-09-08 | Mitsui Toatsu Chemicals, Incorporated | N-(2-chloro-4-trifluoromethylphenyl)-3-trifluoromethylbenzenesulfonamide derivative and agricultural fungicide containing same |
| US5280043A (en) | 1988-10-10 | 1994-01-18 | Smith Kline & French Laboratories Ltd. | Sulphonamido containing phenylalkanoic acids as thromboxane A2 antagonists |
| DE3905075A1 (de) | 1989-02-18 | 1990-08-30 | Hoechst Ag | Benzolsulfonamide und verfahren zu ihrer herstellung |
| EP0472053B1 (en) | 1990-08-20 | 1998-06-17 | Eisai Co., Ltd. | Sulfonamide derivatives |
| WO1996040629A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
-
1997
- 1997-08-22 US US08/917,025 patent/US6284923B1/en not_active Expired - Fee Related
-
1998
- 1998-08-13 WO PCT/US1998/016781 patent/WO1999010320A1/en not_active Ceased
- 1998-08-13 EP EP98939384A patent/EP1005453B1/en not_active Expired - Lifetime
- 1998-08-13 ES ES98939384T patent/ES2245803T3/es not_active Expired - Lifetime
- 1998-08-13 DE DE69827267T patent/DE69827267T2/de not_active Expired - Lifetime
- 1998-08-13 CA CA2301842A patent/CA2301842C/en not_active Expired - Fee Related
- 1998-08-13 AT AT98939384T patent/ATE280756T1/de not_active IP Right Cessation
- 1998-08-13 PT PT98939384T patent/PT1005453E/pt unknown
- 1998-08-13 JP JP2000507650A patent/JP4309041B2/ja not_active Expired - Fee Related
- 1998-08-13 AU AU87824/98A patent/AU748826B2/en not_active Ceased
-
2001
- 2001-05-31 US US09/872,463 patent/US6388131B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514167A5 (enExample) | ||
| CA2301842A1 (en) | Substituted benzene compounds as antiproliferative and cholesterol lowering agents | |
| KR930702292A (ko) | 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체 | |
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2004516314A5 (enExample) | ||
| US10016411B2 (en) | Slow-release conjugates of SN-38 | |
| JP2008514732A5 (enExample) | ||
| JP2005502621A5 (enExample) | ||
| EA009783B1 (ru) | Полиалкиленгликоль с остатком для конъюгации биологически активного соединения | |
| JP2008308501A (ja) | 抗血管形成剤としての新規なフタルイミドミミックスの合成および評価 | |
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JPH101495A5 (enExample) | ||
| JPWO2020260252A5 (enExample) | ||
| JP2002525323A5 (enExample) | ||
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| US7452910B2 (en) | Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties | |
| JP2006508965A5 (enExample) | ||
| JP2006503805A5 (enExample) | ||
| EP2108373B1 (en) | Treatment of tumor metastases and cancer | |
| JP2005538974A5 (enExample) | ||
| JP2004500406A5 (enExample) | ||
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| CA2149691A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
| JP2002523496A5 (enExample) | ||
| EP1857442A3 (en) | Novel antimycobacterial compounds |